JAK2 Selective Inhibitors via Local Quality and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors, such as Tofacitinib, lack selectivity for JAK2, which can lead to off-target effects and reduced efficacy in treating diseases associated with JAK2 mutations like myeloproliferative diseases.
Innovation Solution
Development of compounds of Formula (I) or their pharmaceutically acceptable salts, which exhibit superior selectivity for JAK2, potentially offering improved therapeutic outcomes for diseases involving JAK2 mutations by specifically inhibiting the JAK2 enzyme.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tofacitinib is used as a JAK inhibitor, then JAK enzyme inhibition is achieved, but selectivity for JAK2 is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing specific substituent patterns at defined positions of the pyridine core structure. Different substituents (R1-R6) are placed at specific positions to create localized interactions with JAK2, enhancing selectivity for this specific enzyme while minimizing off-target effects on other JAK family members.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and functional groups in the general formula. These parameter modifications allow optimization of the compound's binding affinity and selectivity profile for JAK2 compared to other JAK isoforms.
2Productivity
If broad-spectrum JAK inhibition is achieved, then multiple cytokine pathways are blocked, but efficacy in JAK2-specific diseases is reduced
Solution Approach 1:
The patent applies segmentation by focusing the inhibitory effect specifically on the JAK2 enzyme rather than uniformly inhibiting all JAK family members. The molecular structure is designed to segment the inhibition profile, targeting JAK2 with high affinity while sparing other isoforms, thereby improving therapeutic efficacy for JAK2-driven diseases.
Solution Approach 2:
The patent uses the specially designed pyridine compound as an intermediary that selectively mediates inhibition of JAK2. This intermediary molecule bridges the gap between the need for effective JAK inhibition and the requirement for JAK2-specific targeting, enabling precise therapeutic action.
Data Source
AI summary
Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.